- AI
- Air Pollution
- Arbitration
- Asia
- Automobile
- Bangladesh
- Banking
- Biodiversity
- Biological Inventions
- bLAWgathon
- Brand Valuation
- Business
- Celebrity Rights
- Company Act
- Company Law
- Competition Law
- Constitutional Law
- Consumer Law
- Consumer Protection Authority
- Copyright
- Copyright Infringement
- Copyright Litigation
- Corporate Law
- Corporate Social Responsibility
- Counterfeiting
- Covid
- CRI Guidelines 2025
- Cyber Law
- Cybersquatting
- Design
- Design Registration in Noida
- Digital Media
- Digital Right Management
- Dispute
- Doping
- Educational Conferences/ Seminar
- Environment Law Practice
- ESIC Act
- EX-Parte
- Farmer Right
- Fashion Law
- FDI
- FERs
- Foreign filing license
- Foreign Law
- Gaming Industry
- GDPR
- Geographical Indication (GI)
- GIg Economy
- Hi Tech Patent Commercialisation
- Hi Tech Patent Litigation
- IBC
- India
- Indian Contract Act
- Indonesia
- Intellectual Property
- Intellectual Property Protection
- IP Commercialization
- IP Licensing
- IP Litigation
- IP Practice in India
- IP registration in the USA
- IPAB
- IPAB Decisions
- IT Act
- IVF technique
- Judiciary
- Khadi Industries
- labour Law
- Legal Case
- Legal Issues
- Lex Causae
- Licensing
- Live-in relationships
- Lok Sabha Bill
- Marriage Act
- Maternity Benefit Act
- Media & Entertainment Law
- Mediation Act
- Member of Parliament
- Mergers & Acquisition
- Myanmar
- NCLT
- NEPAL
- News & Updates
- Non-Disclosure Agreement
- Online Gaming
- Patent Act
- Patent Application Drafting
- Patent Commercialisation
- Patent Description Writing
- Patent Fess
- Patent Filing
- patent infringement
- Patent Landscape
- Patent Licensing
- Patent Litigation
- Patent Marketing
- Patent Opposition
- Patent prosecution in India
- Patent Rule Amendment
- Patents
- Personality rights
- pharma
- Pharma- biotech- Patent Commercialisation
- Pharma/Biotech Patent Litigations
- Pollution
- Posh Act
- Protection of SMEs
- RERA
- Sarfaesi Act
- SEBI
- Section 3(D)
- Signapore
- Social Media
- Sports Law
- Stamp Duty
- Stock Exchange
- Surrogacy in India
- TAX
- Technology
- Telecom Law
- Telecommunications
- Thailand
- Trademark
- Trademark Infringement
- Trademark Litigation
- Trademark Registration in Foreign
- Traditional Knowledge
- UAE
- Uncategorized
- USPTO
- Vietnam
- WIPO
- Women Empower
Expedited examination and non-expedited (normal) examination: Who can file request for examination?
With effect from May 16, 2016 (effective date for Patent (amendment) rules, 2016), provision of expedited examination was introduced in the Patent system of India. This article does not intend to discuss the different timelines within which request for examination has to be filed in different situations, rather article is restricted to the eligibility of … Continue reading Expedited examination and non-expedited (normal) examination: Who can file request for examination?
Read more »Teva held responsible for Induced Infringement of Eli Lilly’s Blockbuster drug ALITMA
24th February, 2017 - 1:41 pm
Categories:
India
IP Litigation
News & Updates
patent infringement
Patents
0 Comments
In Teva Parenteral Medicines, Inc.; APP Pharmaceuticals LLC; Pliva Hrvatska D.O.O.; Teva Pharmaceuticals USA, Inc.; and Barr Laboratories, Inc. (hereinafter referred to be as Defendants/Appellants/Teva) Vs. Eli Lilly & Co. (hereinafter referred to as Plaintiff/Appelle/Eli Lilly) decided by United States Court of Appeals for the Federal Circuit (CAFC) on January 12, 2017, Plaintiff had filed … Continue reading Teva held responsible for Induced Infringement of Eli Lilly’s Blockbuster drug ALITMA
Read more »Obtaining a Certificate of Recognition from DIPP for IPR benefits
“A start-up would now require only a certificate of recognition from the Department of Industrial Policy and Promotion (DIPP) and would not be required to be examined by the inter-ministerial board, as was being done earlier. This is one rapid change that we have brought in,” said Nirmala Sitharaman, Minister of Commerce and Industry in … Continue reading Obtaining a Certificate of Recognition from DIPP for IPR benefits
Read more »Effect of Union Budget, 2017 on the R&D/ Intellectual Property Practices in India
Union budget that was highly waited for (after demonetization) had gained more attention also due to preponing to February 01, 2017. As a matter of fact, every year budget has certain impact on various industries including IP industry and R&D sectors. In this article, we will try to analyze possible effects of 2017 budget on … Continue reading Effect of Union Budget, 2017 on the R&D/ Intellectual Property Practices in India
Read more »India: Do we need Patent Term Extension and Non-Patent Exclusivities for Pharmaceuticals?
India, though in a phase of rapid economic development, still has the bane of poverty. In this country, around 22% of the population is Below the Poverty Line [1], and hence most of the nation’s policies are oriented towards the poor. India’s IP Policy is no different, as the IP legislature in India is mostly … Continue reading India: Do we need Patent Term Extension and Non-Patent Exclusivities for Pharmaceuticals?
Read more »First Symposium of IIPRD in 2017
After successfully conducting several symposiums in 2016, IIPRD is coming up with one-day seminar on software and electronics patent portfolio with focus on preliminary preparation, prosecution, and litigation in India and US. While the programme is being organized in Pune on February 23, the one in Bengaluru will be hosted February 24. The seminar is … Continue reading First Symposium of IIPRD in 2017
Read more »Analysis of the rejection of Lumacaftor (Polymorph) patent application in India
We have been receiving requests from our Pharma clients/readers of the blog for the analysis of the decision/ facts that led to rejection of Lumacaftor (Polymorph) patent application in India since last year. Here is our take: Details of the Patent Application and important dates: Patent application number in India 2056/KOLNP/2010 Title of the invention … Continue reading Analysis of the rejection of Lumacaftor (Polymorph) patent application in India
Read more »A Primer to Patent Application Drafting with special emphasis on standard practise(s) before the Indian Patent Office
An enforceable Patent being the key to effective Commercialization/Out-Licensing of any technology needs to be drafted well. No matter how good a technology is, if the description of the technical subject matter of a Patent is not enabling or fails to disclose all necessary embodiments, and in case the claims are narrowly drafted and do … Continue reading A Primer to Patent Application Drafting with special emphasis on standard practise(s) before the Indian Patent Office
Read more »PATENT INFRINGMENT SUIT BY DOLBY AGAINST OPPO AND VIVO
Anjana Mohan, an intern at Khurana & Khurana, Advocates and IP Attorneys deals with the updates in the Patent Litigation between Dolby International and two Smartphone companies Oppo and Vivo over the patented technology by Dolby. Dolby filed suits vide Suit no CS(COMM) 1425/2016 and CS(COMM) 1426/2016 against various parties including the two major Chinese … Continue reading PATENT INFRINGMENT SUIT BY DOLBY AGAINST OPPO AND VIVO
Read more »Merk’s patent valid but Teva’s Nasonex generic non-infringing
In Merck Sharp & Dohme Corp. (hereinafter referred to be as “Merck”) v. Teva Pharms. United States, Inc. (hereinafter referred to be as “Teva”) decided on November 16, 2016, Teva’s application of Abbreviated New Drug Application (hereinafter referred to as “ANDA”) no. 205149 had triggered Merck to file infringement suit against Teva in respect of … Continue reading Merk’s patent valid but Teva’s Nasonex generic non-infringing
Read more »